Fate of nanostructured lipid carriers (NLCs) following the oral route: Design, pharmacokinetics and biodistribution

Journal of Microencapsulation

Volumn 31, Issue 1, 2014, Pages 1-8

  Beloqui, Ana ^a   Solinís, Mara Angeles ^a   Delgado, Araceli ^b   Évora, Carmen ^b   Isla, Arantxazu ^a   Rodríguez Gascón, Alicia ^a,c  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

^c Laboratory of Pharmacy and Pharmaceutical Technology   (Spain)

Author keywords

Bioavailability; Biodistribution; Lipids; Nanoparticles; NLCs; Spironolactone

Indexed keywords

7ALPHA THIOMETHYLSPIRONOLACTONE; CANRENONE; LIPID; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; PANCREATIN; PEPSIN A; SPIRONOLACTONE; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG FORMULATION; DRUG RELEASE; EPITHELIUM CELL; FREEZE DRYING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF QUANTITATION; MALE; METABOLITE; NONHUMAN; PARTICLE SIZE; RABBIT; RADIOACTIVITY; RAT; SMALL INTESTINE; STOMACH JUICE; SURFACE CHARGE; SYRUP; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ANIMALS; DIURETICS; DRUG CARRIERS; LIPIDS; MALE; NANOSTRUCTURES; RABBITS; SPIRONOLACTONE;

EID: 84893047439     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2013.788090     Document Type: Article

References (45)

1. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: Formulation, process and storage considerations. Adv Drug Deliv Rev, 2006;58:1688-713
2. Bakala N'Goma JC, Amara S, Dridi K, Jannin V, Carrière F. Understanding lipid-digestion processes in the GI tract before designing lipid-based drug-delivery systems. Ther Deliv, 2012;3:105-24
3. Chakraborty S, Shukla D, Mishra B, Singh S. Lipid-An emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm, 2009;73:1-15
4. Charman WN, Stella V. J. 1992. Lymphatic transport of drugs. Boca Rato'n, FL: CRC Press
5. Chen M. Lipid excipients and delivery systems for pharmaceutical development: A regulatory perspective. Adv Drug Deliv Rev, 2008; 60:768-77
6. Chen CC, Tsai TH, Huang ZR, Fang JY. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: Physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm, 2010;74:474-82
7. Dahan A, Hoffman A. The effect of different lipid based formulations on the oral absorption of lipophilic drugs: The ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. Eur J Pharm Biopharm, 2007;67:96-105
8. Dahan A, Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release, 2008;129:1-10
9. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech, 2011; 12:62-76
10. del pozo-Rodríguez A, Solinís MA, Gascón AR, Pedraz JL. Short-And long-Term stability study of lyophilized solid lipid nanoparticles for gene therapy. Eur J Pharm Biopharm, 2009;71:181-9
11. European Pharmacopeia. 2007. Dissolution test for solid dosage forms. 7th edn. 2011
12. Florence AT. Nanoparticle uptake by the oral route: Fulfilling its potential? Drug Discov Today: Technol, 2005;2:75-81
13. Florence AT, Hussain N. Transcytosis of nanoparticle and dendrimer delivery systems: Evolving vistas. Adv Drug Deliv Rev, 2001;50: S69-89
14. Guide for the Care and Use of Laboratory Animals. 2011. Washington, DC: National Academies Press (US
15. Hauss DJ. Oral lipid-based formulations. Adv Drug Deliv Rev, 2007;59: 667-76
16. Jannin V, Musakhanian J, Marchaud D. Approaches for the development of solid and semi-solid lipid-based formulations. Adv Drug Deliv Rev, 2008;60:734-46
17. Kesisoglou F, Panmai S, Wu Y. Nanosizing-Oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev, 2007;59:631-44
18. Konan YN, Gurny R, Allémann E. Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. Int J Pharm, 2002; 233:239-52
19. Krishnaiah YSR. Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs. J Bioequiv Availab, 2010;2:28-36
20. Langguth P, Hanafy A, Frenzel D, Grenier P, Nhamias A, Ohlig T, Vergnault G, Spahn-Langguth H. Nanosuspension formulations for low-soluble drugs: Pharmacokinetic evaluation using spironolactone as model compound. Drug Dev Ind Pharm, 2005;31:319-29
21. Limayem Blouza I, Charcosset C, Sfar S, Fessi H. Preparation and characterization of spironolactone-loaded nanocapsules for paediatric use. Int J Pharm, 2006;325:124-31
22. Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev, 2001;47:165-96
23. Merisko-Liversidge E, Liversidge G. Drug nanoparticles: Formulating poorly water-soluble compounds. Toxicol Pathol, 2008;36:43-8
24. Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: A perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv Drug Deliv Rev, 2011;63:427-40
25. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: A formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci, 2003;18:113-20
26. Muchow M, Maincent P, Müller R. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm, 2008;34:1394-405
27. Müller R, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of the art. Eur J Pharm Biopharm, 2000;50:161-77
28. Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm, 2002;242:121-8
29. Müller RH, Runge S, Ravelli V, Mehnert W, Thünemann AF, Souto EB. Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN-) versus drug nanocrystals. Int J Pharm, 2006;317:82-89
30. Müllertz A, Ogbonna A, Ren S, Rades T. New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. J Pharm Pharmacol, 2010;62:1622-36
31. O'Driscoll CM, Griffin BT. Biopharmaceutical challenges associated with drugs with low aqueous solubility-The potential impact of lipidbased formulations. Adv Drug Deliv Rev, 2008;60:617-24
32. Overdiek HW, Merkus FW. The metabolism and biopharmaceutics of spironolactone in man. RevDrug Metab Drug Interact, 1987;5:273-302
33. Porter C, Trevaskis N, Charman W. Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov, 2007;6:231-48
34. Porter CJH, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev, 2008;60:673-91
35. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci, 2006;29:278-87
36. Pouton CW, Porter CJH. Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. Adv Drug Deliv Rev, 2008;60:625-37
37. Saha GB. 2010. Fundamentals of Nuclear Pharmacy. 6th edn. New York, NY: Springer
38. Szymendera J, Radwan M. Intestinal absorption of pertechnetate: Calculation by the oral-intravenous plasma activity quotients and inverse convolution method. J Nucl Med, 1974;15:314-16
39. Tarr BD, Yalkowsky SH. Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size. Pharm Res, 1989;6:40-3
40. Teeranachaideekul V, Mü ller RH, Junyaprasert VB. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)-Effects of formulation parameters on physicochemical stability. Int J Pharm, 2007;340:198-206
41. Trevaskis NL, Charman WN, Porter CJH. Lipid-based delivery systems and intestinal lymphatic drug transport: A mechanistic update. Adv Drug Deliv Rev, 2008;60:702-16
42. US Food and Drug Administration. Guidance for Industry, Bioanalytical Method Validation. 2001. Rockville: Centre for Drug Evaluation and Research (CDER
43. Venishetty VK, Chede R, Komuravelli R, Adepu L, Sistla R, Diwan PV. Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: A novel strategy to avoid intraduodenal administration. Colloids Surf B Biointerfaces, 2012;95:1-9
44. Williams H, Sassene P, Kleberg K, Bakala N, Goma JC, Calderone M, Jannin V, Igonin A, Partheli A, Marchaud D, Vertommen J, et al. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: Method parameterisation and comparison of in vitro digestion profiles across a range of representative formulations. J Pharm Sci, 2012;101:3360-80
45. Zhang X, Yin J, Kang C, Li J, Zhu Y, Li W, Huang Q, Zhu Z. Biodistribution and toxicity of nanodiamonds in mice after intratracheal instillation. Toxicol Lett, 2010;198:237-43